博纳吐单抗治疗儿童复发/难治性急性淋巴细胞白血病的研究进展  

Progress of blinatumomab in the treatment of relapsed/refractory acute lymphoblastic leukemia in children

作　　者：陈霞(综述)[1] 于洁(审校)[1] Chen Xia;Yu Jie(Department of Hematology and Oncology,Children′s Hospital of Chongqing Medical University,Chongqing 400014,China)

机构地区：[1]重庆医科大学附属儿童医院血液肿瘤科,400014

出　　处：《国际儿科学杂志》2023年第5期312-316,共5页International Journal of Pediatrics

摘　　要：近些年,随着大剂量联合化疗方案的不断改进以及对危险因素认识的加深,儿童急性淋巴细胞白血病的缓解率逐渐提高,但复发/难治性急性淋巴细胞白血病(relapsed/refractory acute lymphoblastic leukemia,r/r ALL)的预后仍不乐观,造血干细胞移植成为这部分患儿的替代治疗方案。随着细胞免疫治疗的发展,儿童r/r ALL的预后有望得到改善。博纳吐单抗作为一种双特异性抗体是第一个在临床试验中进行测试并获得美国FDA批准用于费城染色体(Philadelphia chromosome,Ph)阴性r/r ALL的克隆抗体。博纳吐单抗作为新一代单克隆抗体可改善r/r ALL患儿的生存。该文围绕博纳吐单抗的作用机制与耐药机制、临床研究进展和不良反应方面进行综述。In recent years,with the continuous improvement of high-dose combined chemotherapy and deeper understanding of risk factors,the remission rate of childhood acute lymphoblastic leukemia has been gradually improved,but the prognosis of relapsed/refractory acute lymphoblastic leukemia(r/r ALL)is still not optimistic.Hematopoietic stem cell transplantation has become an alternative treatment for these children.With the development of cellular immunotherapy,the prognosis of children with r/r ALL is expected to be improved.Blinatumomab,as a bispecific antibody,is the first cloned antibody to be tested in clinical trials and approved by FDA for Philadelphia chromosome negative(Ph-)r/r ALL.Blinatumomab as a new generation of monoclonal antibody can significantly improve the survival of children with r/r ALL.This article focuses on the mechanism of action,drug resistance,clinical research progress and adverse reactions of Blinatumomab.

关 键 词：儿童 急性淋巴细胞白血病 难治 复发 博纳吐单抗 

分 类 号：R733.71[医药卫生—肿瘤]